CSPC
M0 CSPC - embark study
CRPC
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC), ARASENS study
PCWG3 criteria
Androgen receptor pathway inhibitors (ARPis)
LOH (16)
HRRm-homologous recombination repair gene mutation
OAR-organ at risk
PSADT, PSA doubling time
